Harrow Inc
NASDAQ:HROW

  • LAST PRICE
    17.9700
  • TODAY'S CHANGE (%)
    0.0300 (0.1672%)
  • Bid / Lots
    16.0000/ 1
  • Ask / Lots
    19.5800/ 1
  • Open / Previous Close
    17.8000 / 17.9400
  • Day Range
    17.0200
    18.2075
  • 52 Week Range
    7.6000
    22.6299
  • Volume
    397,647

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
HROW
Harrow Inc
635.8M
-19.8x
---
ESPR
Esperion Therapeutics Inc
566.5M
-3.0x
---
SIGA
SIGA Technologies Inc
474.4M
6.1x
-28.78%
BVNRY
Bavarian Nordic A/S
1.8B
12.5x
---
EOLS
Evolus Inc
709.4M
-10.8x
---
XERS
Xeris Biopharma Holdings Inc
326.2M
-4.7x
---
As of 2024-06-15

Company Information

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Contact Information

Headquarters
102 WOODMONT BLVD, SUITE 610NASHVILLE, TN, United States 37215
Phone
615-733-4731
Fax
858-345-1745

Executives

Chairman of the Board, Chief Executive Officer
Mark Baum
Chief Financial Officer, Corporate Secretary
Andrew Boll
President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
John Saharek
Lead Independent Director
Perry Sternberg
Independent Director
Adrienne Graves

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$635.8M
Revenue (TTM)
$138.7M
Shares Outstanding
35.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.75
EPS
$-0.91
Book Value
$2.01
P/E Ratio
-19.8x
Price/Sales (TTM)
4.6
Price/Cash Flow (TTM)
---
Operating Margin
-5.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.